Novo Nordisk mini oral: Phenotypic diversity and emerging therapeutic frontiers in heart failure with preserved ejection fraction (HFpEF)
Friday, August 15, 2025 |
3:15 PM - 3:45 PM |
Theatrette 2 |
Speaker
Prof John Atherton
Director of Cardiology
Royal Brisbane and Women's Hospital
Phenotypic diversity and emerging therapeutic frontiers in heart failure with preserved ejection fraction (HFpEF)
3:15 PM - 3:45 PMBiography
Prof John Atherton is a Pre-eminent Staff Specialist and Director of Cardiology at the Royal Brisbane and Women’s Hospital (RBWH); Professor, Faculty of Medicine UQ; Adjunct Professor, Faculty of Health, QUT.
John Atherton is a Pre-eminent Staff Specialist and Director of Cardiology at the Royal Brisbane and Women’s Hospital (RBWH); Professor, Faculty of Medicine, University of Queensland; Adjunct Professor, Faculty of Health, Queensland University of Technology.
Professor Atherton was one of four non-European official content reviewers for the 2016 European Society of Cardiology Heart Failure Guidelines, chaired the 2018 National Heart Foundation of Australia/ Cardiac Society of Australia and New Zealand (CSANZ) Heart Failure Guidelines, and sits on the Therapeutic Guidelines Cardiovascular Expert Group. He recently co-authored the first universal definition of heart failure.
Professor Atherton is Data Custodian for the Queensland Cardiac Outcomes Registry (QCOR) - Heart Failure and sits as a Director on the National Cardiac Registry Board. His clinical and research interests include heart failure disease management, investigating the clinical utility of advanced echocardiography, hypertrophic cardiomyopathy and cardiac genetics.
